Hangzhou Minsheng Pharmaceutical Co. Ltd

Hangzhou Minsheng Institutes for Pharma Research

Hangzhou Minsheng Pharmaceuticals Co., Ltd.

Zhonghua Peng

Dianwu Guo

Ximing Shen

Shulong Wang

Binnan Huang

Qiufu Ge

Lan Yang

Feiyu Feng

Jian Cai

Zhenhua Liu

A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.

Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament

Growing community of inventors

Hangzhou, China

Zhonghua Peng